- Inhibitors
- Antibodies
- Compound Libraries
- New Products
- Contact Us
Synonyms: LIFA, DNIB0600A, RG-7599
Lifastuzumab vedotin (LIFA, DNIB0600A, RG-7599) is an antibody-drug conjugate (ADC) composed of a humanized anti-NaPi2b monoclonal antibody and an anti-mitotic cytotoxic agent, monomethyl auristatin E (MMAE) . Lifastuzumab vedotin is used in the treatment of platinum-resistant ovarian cancer.
CAS No. 1401812-88-1
| Name | Citation | Sodium Channel | Others |
|---|---|---|---|
| A-803467 | 2 | ||
| Camostat Mesilate | 16 | ||
| Ambroxol HCl | 0 | ||
| Flecainide hydrochloride | 0 | ||
| Suzetrigine (VX-548) | 0 | ||
| Tenapanor | 0 | ||
| SEA0400 | 0 | ROS,ERK,p38 MAPK | |
| SLC13A5-IN-1 | 0 | ||
| LTGO-33 | 0 | ||
| EIPA (L593754) | 8 | ||
| Vernakalant (RSD1235) Hydrochloride | 0 | ||
| QX-314 chloride | 0 | ||
| VX-150 | 0 | ||
| Rimeporide | 0 | ||
| (-)-Sparteine Sulfate | 0 | ||
| Benzocaine | 0 | ||
| Tolperisone HCl | 1 | ||
| Vinpocetine | 1 |
| Description |
Lifastuzumab vedotin (LIFA, DNIB0600A, RG-7599) is an antibody-drug conjugate (ADC) composed of a humanized anti-NaPi2b monoclonal antibody and an anti-mitotic cytotoxic agent, monomethyl auristatin E (MMAE) . Lifastuzumab vedotin is used in the treatment of platinum-resistant ovarian cancer.
|
References |
|---|
| CAS No. | 1401812-88-1 |
|---|---|
| ADC antiody | Lifastuzumab |
| ADC cytotoxin | MMAE |
| Formulation | 0.1 MPro-Ac,0.02 MArg-Ac,pH5.0 |
| Storage (From the date of receipt) |
Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles. |
*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.